The combination of the BRAF inhibitor dabrafenib and MEK inhibitor trametinib have FDA approval for treatment of BRAF V600E-mutated NSCLC based on the results of phase II data, with ORR of ~65% in both treatment-naïve and pre-treated patients [96]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.